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 CURRENT
OPINION Biomarkers in sepsis
Mervyn Singer
Purpose of review
This review discusses the current developments in biomarkers for sepsis.
Recent findings
With quantum leaps in technology, an array of biomarkers will become available within the next decade
as point-of-care tools that will likely revolutionize the management of sepsis. These markers will facilitate
early and accurate diagnosis, faster recognition of impending organ dysfunction, optimal selection and
titration of appropriate therapies, and more reliable prognostication of risk and outcome. These diagnostics
will also enable an improved characterization of the biological phenotype underlying sepsis and thus a
better appreciation of the condition.
Summary
The potential for novel biomarkers in sepsis will need to be properly realized with considerable funding,
academic–industry collaborations, appropriate investigations and validation in heterogenous populations,
but these developments do hold the capacity to transform patient care and outcomes.
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INTRODUCTION
The recent inability of activated protein C to show
an outcome benefit in a randomized controlled
multicentre trial [1
&]andthesubsequentwithdrawal
of the product from commercial use add to the
growing stockpile of failed therapeutics for sepsis.
Billions of dollars have been spent on such drugs
that have predominantly focussed on one form or
another of modulation of the systemic inflamma-
tory/immune response underlying sepsis. The likely
utility offered by these agents to some individual
patients has been diluted down in these large
heterogenous trial populations, either by a large
number of patients in whom no benefit was
achieved or, potentially, by a near-equivalent
number of patients who were harmed. In general,
these failed drugs have been consigned to a rear
shelf, but on occasion new roles have been found.
The most stunning example to date is anti-tumour
necrosis factor (TNF) antibody therapy, a dismal
flop in sepsis but a gigantic success in rheumatoid
arthritis and psoriasis. Indeed, anti-TNF antibodies
constitute the top three pharmaceutical best sellers
of 2012 with predicted sales in excess of $26 billion
[2]: impressive progress after an inauspicious start.
The realization is slowly dawning that reliance
on a clinical phenotype of severe sepsis or septic
shock, a strategy that has essentially remained
unchanged for over two decades, is fundamentally
flawed [3]. Greater insights into the disease patho-
physiology have highlighted the lack of agreement
between clinical presentation and immune pheno-
type. Indeed, many critically ill patients exhibit an
overall anti-inflammatory mediator balance even
on admission to an intensive care unit (ICU) [4].
The likelihood of an advantageous response from
further immunosuppression is thus improbable.
Arguably, such patients could gain from judicious
immune stimulation. This has been demonstrated
in small randomized trials using either granulocyte-
macrophage colony stimulating factor [5] or inter-
feron-gamma [6], in which a concurrent improve-
ment in immune cell functionality mirrored the
clinical improvement in previously static patients.
This review article highlights four areasof recent
high-level activity, namely early identification of
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sepsis, early identification of organ dysfunction,
biomarkers to indicate the likely efficacy of a
strategy and prognosticators of outcome.
EARLY IDENTIFICATION OF SEPSIS
At present, sepsis is difficult to diagnose with high
sensitivity and specificity. The protean manifes-
tations of the condition and the clinical and
biochemical similarities to other, noninfective,
systemicinflammatory states(e.g. traumaandblood
transfusion reaction) present multiple challenges to
optimal patient management. Accurately identify-
ing sepsis at an early stage has clearly important
ramifications. Not only can appropriate treatments
be administered promptly, be it antibiotics or radio-
logical/surgical drainage,butalso unnecessary inter-
ventions can be avoided. Thus, antibiotic burden
can be reduced with concomitant reductions in
bacterial resistance, fungal overgrowth, Clostridium
difficile infection and the multiple other compli-
cations of antibiotics such as renal or hepatic
dysfunction. Linking early sepsis recognition with
early pathogen detection (and their antibiotic
resistance patterns) enables directed and effective
therapy to be given sooner, thus maximizing the
chances of success.
Many of the traditional markers of infection are
notable for their inaccuracy. Neutrophil count and
body temperature may be high, normal or low,
whereasC-reactiveproteinlevels,reflectinganacute
phase hepatic response, may be resolutely normal in
the face of overwhelming infection. A high body
temperature may also be a reaction to trauma,
surgery, various drugs and blood product transfu-
sions. For example, Circiumaru et al. [7] reported
that fever (defined as temperature 38.48C) affected
70 of 100 consecutive ICU admissions, but only
16 were attributed alone or in part to infection.
Newer biomarkers have their strong advocates,
yet systematic reviews are less convincing. Procalci-
tonin, a prohormone of calcitonin, is one example
that is heavily promoted; however, Tang et al. [8]
reported a low diagnostic performance for identify-
ing sepsis, with a mean sensitivity and specificity
of 71% [95% confidence interval (CI) 67–76%] and
an area under the receiver operator characteristic
(ROC) curve of 0.78 (95% CI 0.73–0.83). Ideally,
a biomarker should offer values of at 0.90, if not
at 0.95.
Likewise, a meta-analysis on the diagnostic
utility of soluble triggering receptor expressed on
myeloid cells-1 (sTREM-1) was recently performed
on 11 studies comprising 1795 patients [9]. Pooled
sensitivity and specificity were 79% (95% CI 65–
89%) and 80% (95% CI 69–88%), respectively, with
an area under the ROC curve of 0.87 (95% CI 0.84–
0.89). The authors of the review concluded
that plasma sTREM-1 was inadequate as a single
biomarker for diagnosing sepsis.
The challenge with a single inflammatory bio-
marker is to clearly differentiate an infectious from a
noninfectious systemic inflammatory insult. Thus,
an immediate postoperative rise in either marker
may simply reflect the trauma of surgery, however a
maintained level or secondary rise suggests infec-
tion in the absence of other causative factors.
Groups have proposed combination biomarkers as
being more useful. For example, Kofoed et al. [10]
analysed 151 patients of whom 96 had bacterial
infections. The areas under the curve (AUCs) for
the detection of sepsis ranged from 0.50 to 0.81
for, in ascending order, soluble urokinase-type
plasminogen activator (suPAR), sTREM-1, macro-
phage migration inhibitory factor (MIF), procalcito-
nin, neutrophil count and C-reactive protein. Using
the six markers as a composite test, the AUC was
0.88 (95% CI 0.81–0.92), a value significantly
greater than that of any single biomarker. Similarly,
Gibot et al. [11
&&] recently created a ‘bioscore’ from
the serum concentrations of procalcitonin and
sTREM-1, and expression of CD64 on neutrophils
measuredby flow cytometry. Thisscorewassuperior
(AUC 0.97 [95% CI 0.95–0.99]) to any of the
markers used alone (AUC ranging from 0.73–
0.95); in a validation cohort of 79 patients, 90.9%
were correctly classified by this bioscore.
Perhaps the next generation of sepsis diagnosis
markers will rely more on alternative approaches.
For example, preliminary transcriptomic analyses
have identified increased or decreased expression
of genes encoding for proteins in a variety of often
disparate pathways that appear to be a characteristic
KEY POINTS
 Current management of sepsis is complicated, and
patient outcomes are compromised, by the difficulties in
diagnosis, delayed recognition of organ dysfunction
and a poorly characterized biological phenotype.
 The development of new and effective therapies for
sepsis has been severely hampered by an inability to
select individual patients who will most likely benefit
from such treatments, and to precisely titrate dosing
and duration.
 Within the next decade, new technologies promise rapid
point-of-care testing that should considerably augment
diagnostic, therapeutic and prognostic capabilities.
 Considerable research is required to properly validate
these tools and confirm their utility.
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of sepsis. In 92 ICU patients at risk of developing
sepsis, Lukaszewski et al. [12] took daily white cell
samples for the measurement of changes in the
expression of interleukin (IL)-1b, IL-6, IL-8, IL-10,
TNF-a, FasL and CCL2 mRNA by real-time reverse
transcriptasePCR.Neuralnetworksusingthesecyto-
kine and chemokine data correctly predicted the
development of sepsis in 83% of cases at 1–4 days
before the clinical diagnosis was made; this was
achieved with high sensitivity and selectivity
(91.4 and 80.2%, respectively). In a separate study,
Sutherland et al. [13
&] performed leucocyte multi-
gene array and multiplex-tandem PCR studies
to assess the transcriptional profiles in healthy
volunteers and in ICU patients with sepsis or post-
operatively. Using a panel of 42 genes, sepsis could
be predicted with an area under the ROC curve
ranging from 86 to 92%.
Another interesting development is the ability
to differentiate between different septic transcrip-
tomes. Maslove et al. [14] recently analysed neutro-
phils from patients meeting traditional diagnostic
criteria for sepsis to identify two distinct sepsis sub-
types based on the expression patterns in 365 genes.
This separation was independent of the clinical
factors including age, illness severity, mortality
and the requirement for organ support. In the first
subtype, there was a significant increase in the
expression of genes involved in inflammatory and
Toll-like receptor mediated signalling pathways,
and this was associated with a higher prevalence
of severe sepsis. Of interest, expression differed
significantly between the subtypes for genes
involved in pathways relevant to the actions of
drugs used with variable effect in sepsis, including
activated protein C, vasopressin, hydrocortisone
and norepinephrine.
Such analyses may appear at first sight to be
far removed from a rapid diagnostic. However,
impressive technological leaps mean that auto-
mated, small footprint, point-of-care devices such
as multiplex PCR capable of analysing a panel of
mRNA transcripts within hours will be a bedside
reality within a few years.
EARLY IDENTIFICATION OF ORGAN
DYSFUNCTION
A systemic inflammatory response to infection
(sepsis) can lead on to multiple organ dysfunction
(severe sepsis). At present, the tools available for
clinicians to diagnose organ dysfunction are limited
in their capacity to detect early change. Renal
dysfunction is currently diagnosed by a fall in urine
output and a rise in serum urea and creatinine.
However, oliguria may be an appropriate
physiological response to hypovolaemia whereas,
in patients with previously normal kidneys,
creatinine does not rise above normal values until
the glomerular filtration rate has fallen by approxi-
mately 75%. A vast array of blood and urine
biomarkers, of which more than 30 are currently
described, can detect decreases in renal function
(e.g. cystatin C) or direct tubular stress or injury
[e.g. neutrophil gelatinase-associated lipocalin
(NGAL)] at a much earlier stage [15]. In addition,
biomarkers can be used to predict renal recovery
[16
&]. At present, it is unclear which biomarkers best
prognosticate for significant renal dysfunction and
injury, and which can be successfully used to direct
therapy to prevent (or at least ameliorate) acute
kidney injury.
The same applies to the liver where traditional
markers of dysfunction such as hyperbilirubinaemia
and coagulopathy occur relatively late, peaking at
3–5 days after the diagnosis of sepsis [17]. However,
we have recently shown impaired biotransform-
ation and hepatobiliary transport in a rat model
as early as 6h after faecal peritoneal contamination
[18]. This early dysfunction is supported by a
significant rise in plasma bile acids in 48 patients
on the day severe sepsis was diagnosed; unlike
bilirubin (AUC 0.59), bile acid levels predicted
28-day mortality with high sensitivity and speci-
ficity (AUC up to 0.87) [18].
BIOMARKERS TO INDICATE THE LIKELY
EFFICACY OF A STRATEGY OR ITS
TITRATION
With the repeated therapeutic failure of immuno-
modulatory agents for sepsis, there is a growing
recognition of the need for biomarkers that can
indicate both the likely utility of a drug and
how to optimally titrate the dosage [19]. An excel-
lent example is the use of corticosteroids: the use of
these agents has vacillated in and out of favour for
decades. A revival in the use of corticosteroids was
stimulated by the finding in a French multicentre
study that benefit was restricted to the subset of
patients not responding with an appropriate
rise in cortisol to an ACTH stimulation test [20].
However, this could not be reproduced in the
larger CORTICUS study [21], whilst the wide
inter-laboratory and inter-kit variability of ACTH
stimulation testing undermined the validity of
this test [22]. An interesting laboratory study by
Osuchowski et al. [23] found that IL-6 levels taken
at6hafterasepticinsultinmicecoulddifferentiate
between responders and nonresponders to dexa-
methasone, with significant outcome benefit in
the high IL-6 group, and a trend towards harm in
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those with low IL-6 levels. Similar findings were
recently reported in dogs [24].
Perhaps,agoodbiomarkerforactivatedproteinC
may have targeted those patients who could have
benefitted from the therapy. A retrospective analysis
of plasma levelsofprotein Cactivitysuggested worse
outcomes in those septic patients with low levels on
studyenrolmentandinparticular thosewhoselevels
failed to normalize over time [25]. A better response
was achieved in those patients who had received
activated protein C therapy. This provided a biologic
rationale for titrating therapy; however, a phase II
trial in which therapy was titrated according to the
levels failed to support the utility of protein C
activity as a biomarker [26].
Although the sensitivity/specificity of pro-
calcitonin precludes its use as a stand-alone sepsis
diagnostic [8], several studies have used it to allow
earlier cessation of antibiotic therapy [27], though
reductions in antibiotic consumption have not
always been achieved [28]. Arguably, a negative test
provides a comfort blanket to clinicians to provide
the necessary confidence to cease antibiotics,
though the infection may have been eradicated well
beforehand. Of note, a recent study using daily pro-
calcitonin measurements to trigger a drug-escalation
algorithm and intensified diagnostics resulted in
significantly greater antibiotic use, but no improve-
ment in survival, more organ failure and a greater
length of stay in the ICU [29].
PROGNOSTIC BIOMARKERS
Many biomarkers have been shown to be prognostic
fortheeventualoutcomeinICUpatients.Fewstudies
havebeenmulticentreorlargescalebutdoimplythe
dye is cast at an early stage in the patient’s presen-
tation to hospital. A multicentre study of 1886
patients hospitalized with community-acquired
pneumonia revealed a strong association between
plasma cytokine levels and 90-day mortality, with
the worst outcomes seen in the subset with elevated
levels of both pro-inflammatory and anti-inflamma-
tory cytokines (IL-6 and IL-10, respectively) [30].
Another multicentre study performed in 10 emer-
gency departments found a biomarker panel of
NGAL, protein C and IL-1 receptor antagonist
predicted severe sepsis, septic shock and death with
AUCsforaccuracyof0.80,0.77and0.79,respectively
[31].
Other studies have shown prognostic capability
frombiomarkersofphysiologicalorbiochemicalper-
turbation:forexample,heartrate[32],lactate[33,34]
and autonomic dysfunction [35]; immunological,
inflammatory, coagulation and endothelial acti-
vation markers [36–41]; markers of bioenergetic–
metabolic abnormality [33,34,42–44]; hormone
levels[37,45,46]; markersoforganfunction/damage,
for example, echocardiographic markers [47],
troponins [48], B-type natriuretic peptides [49] and
markers of brain injury [50]; and a range of stand-
alone biomarkers including plasma DNA, nucleated
red blood cells and faecal pH [51–53].
Importantly, none have shown the ability to
completely differentiate between survivors and non-
survivors. These markers represent a wide range of
perturbed body systems and this underlies the com-
plex,multisystempathophysiologyofthecondition.
CONCLUSION
New biomarkers will revolutionize the manner
in which sepsis is managed, in terms of early
recognition, targeting and titration of therapy,
and prognostication. Point-of-care technologies will
facilitate both measurement and patient manage-
ment. It is also likely to benefit trial design and
enable putative therapies to be better evaluated.
For example, survival studies can be focussed upon
those people predicted to be at high risk of dying,
whereas a specific immunomodulatory agent can be
targeted at those with raised or depressed levels, as
appropriate. Importantly, these biomarkers need to
be validated in large multicentre studies, including
heterogenous subsets with respect to age, sex, race,
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